B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL [Phase 1]
Phase 1 clinical trial update for Kappa-CD28 T lymphocytes in chronic lymphocytic leukemia, B-cell lymphoma, and multiple myeloma. The study…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Family Study of Lymphoproliferative Disorders
A Mayo Clinic-led clinical trial is a family study investigating lymphoproliferative disorders, currently in the recruitment phase.
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies [Phase 1]
Phase 1 trial update examining loncastuximab tesirine with DA-EPOCH-R for previously untreated aggressive B-cell lymphoid malignancies; the …
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 study update for IKS03 in advanced B-cell non-Hodgkin lymphomas is currently recruiting across multiple subtypes including diffuse l…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors [EARLY_Phase 1]
A phase 1 clinical trial of BAFFR CAR-T therapy for relapsed/refractory B-cell tumors is not yet recruiting, sponsored by Guangzhou Bio-gene…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies [Phase 1]
A Phase 1 clinical trial update for CD19-directed CAR-T cell therapy in patients with refractory or relapsed B lymphoid malignancies is curr…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma [Phase 1]
This document describes a Phase 1 clinical trial evaluating LP-168 in participants with relapse or refractory B-cell lymphoma. The study is …
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas [Phase 1]
Phase 1 trial evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. [Phase 1, Phase 2]
This Phase I/II open-label trial evaluates an anti-CD19/CD22 CAR-T cell therapy in adults with relapsed or refractory acute lymphoblastic le…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Early Assessment of Cardiac Function After Treatment With CAR-T Cells
A clinical trial update reporting early cardiac function assessment in patients treated with CAR-T cell therapy for hematologic malignancies…
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) [Phase 1]
Phase 1 FT522-101 study evaluating FT522 in combination with Rituximab for relapsed/refractory B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) [Phase 1]
Phase 1 trial CITADEL-112 evaluating INCB050465 in combination with Rituximab, Bendamustine with Rituximab, or Ibrutinib in previously treat…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas [Phase 1]
Phase 1 feasibility trial evaluating the combination of tazemetostat with CAR T-cell therapy in B-cell lymphomas, including follicular lymph…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.
An ongoing clinical trial update notes occurrences of acute kidney injury after CD19-directed CAR-T cell therapy in patients with B-cell lym…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the efficacy and safety of CD19CD20-CAR.p40-T in relapsed/refractory B-cell lymphoma and is current…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma [Phase 2]
Phase 2 study of a dual CD22/CD19 CAR-T therapy as first-line consolidation for B-cell lymphoma, with the trial currently active but not rec…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL [Phase 1, Phase 2]
A Phase 1/2 study of an allogeneic CD19-targeting CAR-γδT cell therapy (QH103E) for relapsed/refractory non-Hodgkin lymphoma is currently re…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma [Phase 1]
This entry provides an update on an ongoing Phase 1 clinical study of a multi-targeted CAR-T therapy for relapsed/refractory B-cell lymphoma…
-
CLINICAL_TRIALS research · 2025-07-28Clinical Trial Update: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies [Phase 1, Phase 2]
This document outlines a Phase I/II clinical trial of ALETA-001 for various B-cell lymphomas, with recruitment ongoing and sponsored by Canc…
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies [Phase 2]
Phase 2 clinical trial update evaluating a bridging regimen containing mitoxantrone hydrochloride liposome injection together with CD19-targ…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors [EARLY_Phase 1]
This is an early-phase study evaluating allogeneic CD19/BCMA CAR-T cells for relapsed/refractory B-cell malignancies, currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: CD30 CAR-T in the Treatment of CD30 Positive Lymphoma [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating a CD30-targeted CAR-T therapy for CD30-positive lymphomas is listed as not yet recruiting, sponso…
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL [Phase 1]
Phase 1 clinical trial evaluating autologous CD19-specific CAR T cells (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma, chronic …